

Publicacions Servei de Microbiologia 2014.

1. Cabrerizo M, Trallero G, Pena MJ, Cilla A, Megias G, Munoz-Almagro C, Del Amo E, Roda D, Mensalvas AI, Moreno-Docon A, Garcia-Costa J, Rabella N, Omenaca M, Romero MP, Sanbonmatsu-Gamez S, Perez-Ruiz M, Santos-Munoz MJ, Calvo C. **Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life.** Eur J Pediatr. 2015;174(11):1511-6.

IF: 1.890 *43/120 Q2 (PEDIATRICS) 2014

[Veure Document / Ver Documento / See Document](#)

2. Catala A, Roe E, Dalmau J, Pomar V, Muñoz C, Yelamos O, Puig L. **Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature.** Dermatology. 2015;230(3):204-7.

IF: 1.569 *31/62 Q3 (DERMATOLOGY) 2014

[Veure Document / Ver Documento / See Document](#)

3. Espinel-Ingroff A, Alvarez-Fernandez M, Canton E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadiis J, Morris AJ, Pelaez T, Quindos G, Rodriguez-Iglesias M, Sanchez-Reus F, Shoham S, Wengenack NL, Borrell Sole N, Echeverria J, Esperalba J, Gomez GdlPE, Garcia Garcia I, Linares MJ, Marco F, Merino P, Peman J, Perez Del Molino L, Rosello Mayans E, Rubio Calvo C, Ruiz Perez de Pipaon M, Yague G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J. **Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.** Antimicrob Agents Chemother. 2015;59(11):6725-32.

IF: 4.476 *19/119 Q1 (MICROBIOLOGY) & *27/254 Q1 (PHARMACOLOGY & PHARMACY) 2014

[Veure Document / Ver Documento / See Document](#)

4. Fernandez-Martinez M, Miro E, Ortega A, Bou G, Gonzalez-Lopez JJ, Oliver A, Pascual A, Cercenado E, Oteo J, Martinez-Martinez L, Navarro F. **Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain.** Int J Antimicrob Agents. 2015;46(2):157-63.

IF: 4.296 *21/119 Q1 (MICROBIOLOGY), *34/254 Q1 (PHARMACOLOGY & PHARMACY) & *14/78 Q1 (INFECTIOUS DISEASES) 2014

[Veure Document / Ver Documento / See Document](#)

5. Garcia-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcarcel D, Sierra J. **Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.** Bone Marrow Transplant. 2015;50(4):579-84.
IF: 3.570 *19/68 (HEMATOLOGY) *53/148 IMMUNOLOGY *70/211 (ONCOLOGY) & *8/25 (TRANSPLANTATION) 2014
[Veure Document / Ver Documento / See Document](#)
6. Garcia-Jimenez A, Prim N, Crusi X, Benito N. **Septic arthritis due to Clostridium ramosum.** Semin Arthritis Rheum. 2015.
IF: 3.925 *8/32 Q2 (RHEUMATOLOGY) 2014
[Veure Document / Ver Documento / See Document](#)
7. González V, Fernández G, Dopico E, Margall N, Esperalba J, Muñoz C, Castro E, Sulleiro E, Matas L. **Evaluation of the Vitros Syphilis TPA chemiluminescence immunoassay as a first-line method for reverse syphilis screening.** J Clin Microbiol. 2015;53(4):1361-4.
IF: 3.993 *26/119 Q1 (MICROBIOLOGY) 2014
[Veure Document / Ver Documento / See Document](#)
8. Margall N, March F, Espanol M, Torras X, Gallego A, Coll P. **Two unusual hepatitis C virus subtypes, 2j and 2q, in Spain: Identification by nested-PCR and sequencing of a NS5B region.** J Virol Methods. 2015;223:105-8.
IF: 1.781 *25/33 Q4 (VIROLOGY) *93/162 Q3 (BIOTECHNOLOGY & APPLIED MICROBIOLOGY) *54/79 Q3 (BIOCHEMICAL RESEARCH METHODS) 2014
[Veure Document / Ver Documento / See Document](#)
9. Marti-Carrizosa M, Sanchez-Reus F, March F, Canton E, Coll P. **Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.** Antimicrob Agents Chemother. 2015;59(6):3570-3.
IF: 4.476 *19/119 Q1 (MICROBIOLOGY) & *27/254 Q1 (PHARMACOLOGY & PHARMACY) 2014
[Veure Document / Ver Documento / See Document](#)
10. Mico M, Navarro F, de Miniac D, Gonzalez Y, Brell A, Lopez C, Sanchez-Reus F, Mirelis B, Coll P. **Efficacy of the FilmArray blood culture identification panel for direct molecular diagnosis of infectious diseases from samples other than blood.** J Med Microbiol. 2015;64(12):1481-8.
IF: 2.248 *73/119 Q3 (MICROBIOLOGY) 2014
[Veure Document / Ver Documento / See Document](#)

11. Oteo J, Alcaraz R, Bou G, Conejo C, Diaz-Lamas AM, Fernandez-Martinez M, Fontanals D, González-López JJ, López-Contreras J, Martínez-Martínez L, Mora-Rillo M, Muñoz M, Navarro F, Oliver A, Pintado V, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Sánchez-Porto A, Sánchez-Romero I, Zamorano L, Aracil B, Rodríguez-Baño J. **Rates of faecal colonization by carbapenemase-producing *Enterobacteriaceae* among patients admitted to ICUs in Spain.** J Antimicrob Chemother. 2015;70(10):2916-8. IF: 5.313 *8/78 Q1 (INFECTIOUS DISEASES) *17/119 Q1 (MICROBIOLOGY) & *17/254 Q1 D1 (PHARMACOLOGY & PHARMACY) 2014

[Veure Document / Ver Documento / See Document](#)

12. Oteo J, Ortega A, Bartolome R, Bou G, Conejo C, Fernandez-Martinez M, Gonzalez-Lopez JJ, Martinez-Garcia L, Martinez-Martinez L, Merino M, Miro E, Mora M, Navarro F, Oliver A, Pascual A, Rodriguez-Bano J, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Zamorano L, Bautista V, Perez-Vazquez M, Campos J. **Prospective multicenter study of carbapenemase-producing *Enterobacteriaceae* from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.** Antimicrob Agents Chemother. 2015;59(6):3406-12. IF: 4.476 *19/119 Q1 (MICROBIOLOGY) & *27/254 Q1 (PHARMACOLOGY & PHARMACY) 2014

[Veure Document / Ver Documento / See Document](#)

13. Pascual V, Ortiz G, Simó M, Alonso N, García MC, Xercavins M, Rivera A, Morera MA, Miró E, Espejo E, Navarro F, Gurguí M, Pérez J, Rodríguez-Carballeira M, Garau J, Calbo E. **Epidemiology and risk factors for infections due to AmpC beta-lactamase-producing *Escherichia coli*.** J Antimicrob Chemother. 2015;70(3):899-904. IF: 5.313 *8/78 Q1 (INFECTIOUS DISEASES) *17/119 Q1 (MICROBIOLOGY) & *17/254 Q1 D1 (PHARMACOLOGY & PHARMACY) 2014

[Veure Document / Ver Documento / See Document](#)

14. Prim N, Rivera A, Espanol M, Mirelis B, Coll P. **In Vivo Adaptive Resistance to Colistin in *Escherichia coli* Isolates.** Clin Infect Dis. 2015;61(10):1628-9. IF: 8.886 *2/78 Q1 D1(INFECTIOUS DISEASES) *9/119 Q1 D1(MICROBIOLOGY) & *9/148 Q1 D1(IMMUNOLOGY) 2014

[Veure Document / Ver Documento / See Document](#)

15. Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P. **Inducible and Acquired Clarithromycin Resistance in the *Mycobacterium abscessus* Complex.** PLoS ONE. 2015;10(10):e0140166.

IF: 3.234 *8/56 Q1 (MULTIDISCIPLINARY SCIENCES) 2014

[Veure Document / Ver Documento / See Document](#)

16. Segura R, Prim N, Montemayor M, Valls ME, Muñoz C. **Predominant virulent IbA10G2 subtype of *Cryptosporidium hominis* in human isolates in Barcelona: a five-year study.** PLoS ONE. 2015;10(3):e0121753.

IF: 3.234 *8/56 Q1 (MULTIDISCIPLINARY SCIENCES) 2014

[Veure Document / Ver Documento / See Document](#)

17. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, García-Bellmunt L, Castillo D, Vidal S, Sánchez-Reus F, Restrepo MI, Chalmers JD. **Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.** *Respirology*. 2015;20(7):1082-8.

IF: 3.345 *15/57 Q2 (RESPIRATORY SYSTEM) 2014

[Veure Document / Ver Documento / See Document](#)

18. Zamorano L, Miró E, Juan C, Gómez L, Bou G, González-López JJ, Martínez-Martínez L, Aracil B, Conejo MC, Oliver A, Navarro F. **Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC beta-Lactamases or Carbapenemases from *Enterobacteriaceae*: Findings from a Multicenter Study in Spain.** *Antimicrob Agents Chemother*. 2015;59(9):5260-6.

IF: 4.476 *19/119 Q1 (MICROBIOLOGY) & *27/254 Q1 (PHARMACOLOGY & PHARMACY) 2014

[Veure Document / Ver Documento / See Document](#)

Formant part de grups d'estudi:

1. Puig-Asensio M, Ruiz-Camps I, Fernandez-Ruiz M, Aguado JM, Muñoz P, Valerio M, Delgado-Iribarren A, Merino P, Bereciartua E, Fortun J, Cuenca-Estrella M, Almirante B, CANDIPOP Project Geih-gemicomed seimc (Sánchez F). **Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain.** *Clin Microbiol Infect*. 2015;21(5):491 e1-10.

IF: 5.768 *5/78 Q1 D1 (INFECTIOUS DISEASES) *16/119 Q1 (MICROBIOLOGY) 2014

[Veure Document / Ver Documento / See Document](#)

2. Fernandez-Ruiz M, Puig-Asensio M, Guinea J, Almirante B, Padilla B, Almela M, Diaz-Martin A, Rodriguez-Bano J, Cuenca-Estrella M, Aguado JM, CANDIPOP Project Geih-gemicomed (seimc) (Sanchez F). **Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance.** *J Infect*. 2015;71(3):385-94.

IF: 4.441 *13/78 Q1 (INFECTIOUS DISEASES) 2014

[Veure Document / Ver Documento / See Document](#)

3. Cuervo G, Puig-Asensio M, Garcia-Vidal C, Fernandez-Ruiz M, Peman J, Nucci M, Aguado JM, Salavert M, Gonzalez-Romo F, Guinea J, Zaragoza O, Gudíol C, Carratala J, Almirante B, CANDIPOP Project (Sánchez F). **A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains.** *Clin Microbiol Infect*. 2015;21(7):684 e1-9.

IF: 5.768 *5/78 Q1 D1 (INFECTIOUS DISEASES) *16/119 Q1 (MICROBIOLOGY) 2014

[Veure Document / Ver Documento / See Document](#)